GLAB — Gemina Laboratories Share Price
0.000.00%
Last trade - 00:00- CA$85.76m
- CA$87.18m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Jan | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Gemina Laboratories Ltd. is a Canada-based biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers testing platforms for a range of pathogens that affect human health and wellness. The Company operates in the in vitro diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. Its development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. It operates within a single segment, being the research, development and commercialization of in-vitro diagnostics. Its technologies include dual affinity binding mechanism, gold binding protein, cellulose binding protein and more surface binding proteins. Its products include LEGIO X, which is a COVID-19 rapid antigen test, and LEGIO XI, which is a multiplex device that can detect and distinguish between influenza types A and B with no cross reactivity. LEGIO products in development include respiratory syncytial virus and tuberculosis.
Directors
- Last Annual
- January 31st, 2024
- Last Interim
- October 31st, 2024
- Incorporated
- October 10th, 2017
- Public Since
- August 10th, 2021
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 74,574,272
- Address
- 3800 Westbrook Mall, Suite 142, VANCOUVER, V6S 2L9
- Web
- https://www.geminalabs.com/
- Phone
- +1 6047633191
- Auditors
- Davidson & Company LLP
Upcoming Events for GLAB
Q4 2024 Gemina Laboratories Ltd Earnings Release
Q1 2025 Gemina Laboratories Ltd Earnings Release
Q2 2025 Gemina Laboratories Ltd Earnings Release
Q2 2025 Gemina Laboratories Ltd Earnings Release
Similar to GLAB
Aquarius Surgical Technologies
Canadian Securities Exchange
Cannabix Technologies
Canadian Securities Exchange
Cognetivity Neurosciences
Canadian Securities Exchange
Diagnostear Technologies
Canadian Securities Exchange
Imagin Medical
Canadian Securities Exchange
FAQ
What is the Gemina Laboratories share price?
As of Today at 20:46 UTC, shares in Gemina Laboratories are trading at CA$1.15. This share price information is delayed by 15 minutes.
How has the Gemina Laboratories share price performed this year?
Shares in Gemina Laboratories last closed at CA$1.15 and the price had moved by +134.69% over the past 365 days. In terms of relative price strength the Gemina Laboratories share price has outperformed the Toronto Stock Exchange 300 Composite Index by +111.55% over the past year.
What are the analyst and broker recommendations for Gemina Laboratories?
There is no consensus recommendation for this security.
Find out moreWhat is the Gemina Laboratories dividend yield?
Gemina Laboratories does not currently pay a dividend.
Does Gemina Laboratories pay a dividend?
Gemina Laboratories does not currently pay a dividend.
When does Gemina Laboratories next pay dividends?
Gemina Laboratories does not currently pay a dividend.
How do I buy Gemina Laboratories shares?
To buy shares in Gemina Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Gemina Laboratories?
As of the previous close price of CA$1.15, shares in Gemina Laboratories had a market capitalisation of CA$85.76m.
Where are Gemina Laboratories shares listed?
Here are the trading details for Gemina Laboratories:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: GLAB
What kind of share is Gemina Laboratories?
Based on an overall assessment of its quality, value and momentum Gemina Laboratories is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Gemina Laboratories share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Gemina Laboratories share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gemina Laboratories. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +235.78%.
As of the last closing price of CA$1.15, shares in Gemina Laboratories were trading +92.11% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Gemina Laboratories PE Ratio?
The Gemina Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$1.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Gemina Laboratories?
We do not have data on Gemina Laboratories' directors